ElsaLys Biotech acquires rights of Transgene's anti-CD115 antibody

ElsaLys Biotech acquires rights of Transgene's anti-CD115 antibody


Initially developed by TRANSGENE, one of ELSALYS BIOTECH's founding shareholders, this antibody inhibits a deleterious subpopulation of macrophages found in the tumor microenvironment. Based on the initial preclinical data, ELSALYS BIOTECH will give priority to developing ELB 041 in immuno-oncology, the goal being to launch a first clinical trial in 24 months.



from Biotech News